These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 6320451)
21. Current status of the therapy of advanced renal carcinoma. Hrushesky WJ; Murphy GP J Surg Oncol; 1977; 9(3):277-88. PubMed ID: 327158 [TBL] [Abstract][Full Text] [Related]
22. Metastatic renal cell carcinoma arising in a congenital solitary kidney. Treatment with interferon-containing combinations. A case report and a review of the literature. Merimsky O; Laufer R; Chaitchik S J Urol (Paris); 1989; 95(4):243-5. PubMed ID: 2529317 [TBL] [Abstract][Full Text] [Related]
23. [Individual therapy of the metastatic mammary carcinoma (author's transl)]. Schönfelder M Arch Geschwulstforsch; 1980; 50(7):640-6. PubMed ID: 6263208 [TBL] [Abstract][Full Text] [Related]
24. Chemotherapy of metastatic renal cancer. Denis L; Van Oosterom A Semin Surg Oncol; 1988; 4(2):91-4. PubMed ID: 3293156 [TBL] [Abstract][Full Text] [Related]
26. Cytotoxic chemotherapy for advanced renal cell carcinoma. Yagoda A; Petrylak D; Thompson S Urol Clin North Am; 1993 May; 20(2):303-21. PubMed ID: 8493752 [TBL] [Abstract][Full Text] [Related]
27. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma. Tomic R; Ljungberg B; Damber JE Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122 [No Abstract] [Full Text] [Related]
31. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil]. May M; Helke C; Bock M; Hoschke B Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686 [TBL] [Abstract][Full Text] [Related]
32. The effect of hormonal therapy on a transplantable renal cortical adenocarcinoma in syngeneic mice. Soloway MS; Myers GH J Urol; 1973 Mar; 109(3):356-61. PubMed ID: 4692365 [No Abstract] [Full Text] [Related]
33. Management of breast cancer. Cohen IA; Keller JH; Abate MA Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963 [TBL] [Abstract][Full Text] [Related]
35. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer]. Dryzhak VI Vopr Onkol; 1989; 35(7):771-8. PubMed ID: 2528239 [No Abstract] [Full Text] [Related]
36. [Medical treatment of malignant bone tumors (carcinolytics, hormonotherapy, immunotherapy)]. Clavel B Sem Hop; 1974 Jan; 50(4):287-95. PubMed ID: 4368180 [No Abstract] [Full Text] [Related]
37. [Chemotherapy of endometrial cancer revisited]. Fehr MK; Wight E; Haller U Gynakol Geburtshilfliche Rundsch; 1999; 39(3):110-20. PubMed ID: 10420053 [TBL] [Abstract][Full Text] [Related]
38. Advanced adenocarcinoma of the kidney: therapy with lomustine, vinblastine, hydroxyurea, and medroxyprogesterone acetate and regression analysis of factors relating to survival. Brubaker LH; Troner MB; Birch R Cancer Treat Rep; 1983; 67(7-8):741-2. PubMed ID: 6223695 [No Abstract] [Full Text] [Related]
39. [Progestins in combined treatment of endometrial cancer]. Voznyĭ EK; Titova VA Sov Med; 1990; (9):102-7. PubMed ID: 2148437 [No Abstract] [Full Text] [Related]
40. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Dauvois S; Geng CS; Lévesque C; Mérand Y; Labrie F Cancer Res; 1991 Jun; 51(12):3131-5. PubMed ID: 2039992 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]